Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$156.32+0.3%$159.24$140.68▼$169.99$376.12B0.497.92 million shs9.59 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson+0.35%-1.13%-4.72%+3.06%+6.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJNJJohnson & Johnson4.6276 of 5 stars3.33.04.23.92.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJNJJohnson & Johnson 2.63Moderate Buy$171.829.92% UpsideCurrent Analyst Ratings BreakdownLatest JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2025JNJJohnson & JohnsonBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.004/16/2025JNJJohnson & JohnsonSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform4/16/2025JNJJohnson & JohnsonRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.004/16/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$164.00 ➝ $169.004/14/2025JNJJohnson & JohnsonRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$165.00 ➝ $162.004/10/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$171.00 ➝ $159.004/9/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$163.00 ➝ $164.004/9/2025JNJJohnson & JohnsonThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$157.00 ➝ $172.004/2/2025JNJJohnson & JohnsonRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJNJJohnson & Johnson$89.33B4.21$12.84 per share12.17$29.69 per share5.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJNJJohnson & Johnson$14.07B$8.9923.5114.122.5618.20%34.24%13.63%7/16/2025 (Estimated)Latest JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJNJJohnson & Johnson$5.203.33%+5.43%57.84%64 YearsLatest JNJ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJNJJohnson & Johnson0.431.110.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipJNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJNJJohnson & Johnson152,7002.41 billion2.40 billionOptionableJNJ HeadlinesRecent News About These CompaniesIs Johnson & Johnson (JNJ) the Best Dow Stock for the Next 12 Months?April 30 at 7:03 PM | msn.comJohnson & Johnson Shareholders Approve 2025 Director NomineesApril 30 at 5:36 PM | tipranks.comJohnson & Johnson (JNJ): Jim Cramer Says “They Love the Weak Dollar” — Is This Quiet Giant Back in Favor?April 30 at 4:36 PM | insidermonkey.comJohnson & Johnson (NYSE:JNJ) Trading Up 0.7% - What's Next?April 30 at 2:26 PM | marketbeat.comFDA Approves Johnson & Johnson's IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for FamiliesApril 30 at 1:42 PM | globenewswire.comFDA Greenlights Johnson & Johnson's gMG Treatment Imaavy (JNJ)April 30 at 10:25 AM | gurufocus.comJohnson & Johnson (JNJ) Gains FDA Approval for Imaavy in Treating gMG | JNJ Stock NewsApril 30 at 9:33 AM | gurufocus.comUS FDA approves J&J's immune disorder drugApril 30 at 8:41 AM | reuters.comJohnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)April 30 at 8:29 AM | prnewswire.comSchonfeld Strategic Advisors LLC Sells 265,824 Shares of Johnson & Johnson (NYSE:JNJ)April 30 at 8:19 AM | marketbeat.comAQR Capital Management LLC Purchases 313,672 Shares of Johnson & Johnson (NYSE:JNJ)April 30 at 7:50 AM | marketbeat.comPerbak Capital Partners LLP Acquires Shares of 10,748 Johnson & Johnson (NYSE:JNJ)April 30 at 7:32 AM | marketbeat.comDark Forest Capital Management LP Has $234,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)April 30 at 4:36 AM | marketbeat.comJohnson & Johnson's TAR-200 for Bladder Cancer Shows High Rates of Disease-Free Survival, Bladder PreservationApril 30 at 4:33 AM | appliedclinicaltrialsonline.comJohnson & Johnson (JNJ): Among the Most Profitable Blue Chip Stocks to Buy NowApril 30 at 4:33 AM | msn.comJohnson & Johnson (JNJ): Among the Best Long-Term Dividend Stocks to Buy According to BillionairesApril 30 at 4:33 AM | msn.comJohnson & Johnson (NYSE:JNJ) Shares Unloaded Rep. Robert Bresnahan, Jr.April 30 at 2:05 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Trading 0.4% Higher - Should You Buy?April 29 at 2:38 PM | marketbeat.comCalifornia State Teachers Retirement System Sells 79,227 Shares of Johnson & Johnson (NYSE:JNJ)April 29 at 7:59 AM | marketbeat.comNorthern Trust Corp Purchases 3,363,235 Shares of Johnson & Johnson (NYSE:JNJ)April 29 at 7:53 AM | marketbeat.comThe Manufacturers Life Insurance Company Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)April 29 at 7:49 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.By Leo Miller | April 28, 2025View 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? By Chris Markoch | April 16, 2025View Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? JNJ Company DescriptionsJohnson & Johnson NYSE:JNJ$156.32 +0.41 (+0.26%) As of 03:59 PM EasternJohnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
